Pledget-assisted hemostasis to fix residual access-site bleedings after double pre-closure technique

Table 1 Main characteristics of study population

	Patients
Patient number	15
Age, yr (mean ± SD)	80.0 ± 7.2
Female gender	10 (66.7%)
BMI, kg/m2 (mean ± SD)	27.41 ± 3.6
Risk factors
Diabetes	2 (13.3%)
Hypertension	13 (86.7%)
Dyslipidemia	6 (40.0%)
Smoking	0
Medical history/comorbidities
Chronic kidney disease (not on dialysis)	3 (20.0%)
Chronic dialysis	0
Peripheral artery disease	2 (13.3%)
Atrial Fibrillation	8 (53.3%)
Previous stroke	2 (13.3%)
Chronic pulmonary disease	2 (13.3%)
Previous myocardial infarction	2 (13.3%)
Previous PCI	4 (26.7%)
Previous CABG	1 (6.7%)
STS mortality	3.7 ± 2.5
TAVR score	2.69 ± 0.7
Anticoagulant and antiplatelet therapy
Anticoagulants	7 (46.6%)
Dual antiplatelet therapy	6 (40%)
Clopidogrel	11 (73.3%)
Acetyl salicylic acid	8 (53.3%)

PCI: Percutaneous coronary intervention; CABG: Coronary artery bypass grafting; STS: Society of Thoracic Surgeons; TAVR: Transcatheter-aortic-valve-replacement; SD: Standard deviation.